Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Esperion TherapeuticsESPR -0.31%41 Cash-to-Debt is 0.62 as of Mar. 2026, which is 33% below its 10-year median of 0.92. GuruFocus rates ESPR with a GF Score™ of 41/100 and a GF Value™ of $2.28 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 983 Drug Manufacturers companies, Esperion Therapeutics ranks worse than 58.49% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Esperion Therapeutics's cash to debt ratio for the quarter that ended in Mar. 2026 was 0.62.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Esperion Therapeuticscouldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for Esperion Therapeutics's Cash-to-Debt or its related term are showing as below:
ESPR'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29 Med: 0.92 Max: No Debt
Current: 0.62
During the past 13 years, Esperion Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.29. And the median was 0.92.
ESPR's Cash-to-Debt is ranked worse than 58.49% of 983
companies
in the Drug Manufacturers industry
Industry Median: 0.98
vs ESPR: 0.62
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Esperion Therapeutics Cash-to-Debt Related Terms
Esperion Therapeutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Esperion Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Esperion Therapeutics Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Esperion Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Esperion Therapeutics (ESPR) has a Cash-to-Debt of 0.62 as of Mar. 2026. This is 33% below median its historical median of 0.92. Over the past decade, Esperion Therapeutics' Cash-to-Debt has ranged from 0.29 to 10,000.00. According to the industry distribution chart, Esperion Therapeutics ranks #575 out of 983 companies in the Drug Manufacturers industry, placing it in the top 58.5%.
Is Esperion Therapeutics' Cash-to-Debt too high?
Esperion Therapeutics' current Cash-to-Debt of 0.62 is 33% below median its 10-year median of 0.92. Over the past 10 years, this metric has ranged from a low of 0.29 to a high of 10,000.00. The Drug Manufacturers industry median Cash-to-Debt is 0.98. Esperion Therapeutics' value of 0.62 is 36.7% below this industry median. Based on the distribution chart, Esperion Therapeutics ranks #575 out of 983 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Esperion Therapeutics has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Esperion Therapeutics' Cash-to-Debt compare to AMPH and NIKA?
According to the Drug Manufacturers industry distribution chart, Esperion Therapeutics ranks #575 out of 983 companies for Cash-to-Debt. This places Esperion Therapeutics in the lower half of its industry. The industry median Cash-to-Debt is 0.98. Esperion Therapeutics' value of 0.62 is 36.7% below this benchmark. Historically, Esperion Therapeutics' own Cash-to-Debt has ranged from 0.29 to 10,000.00 over the past decade. While the company's 10-year median is 0.92 vs. the industry median of 0.98, Esperion Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.98, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Esperion Therapeutics's current Cash-to-Debt of 0.62 is 36.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Esperion Therapeutics's current Cash-to-Debt is 0.62, which is 33% below median its own 10-year median of 0.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Esperion Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Esperion Therapeutics (ESPR) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.28, compared to a current price of $3.18 — trading 39.5% above its estimated fair value. The current Cash-to-Debt is 0.62, which is 33% below median its 10-year median of 0.92 and 36.7% below the Drug Manufacturers industry median of 0.98. Esperion Therapeutics' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Esperion Therapeutics (ESPR), the current Cash-to-Debt is 0.62 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Esperion Therapeutics (ESPR) Overvalued in 2026?
Based on GuruFocus' analysis, Esperion Therapeutics stock appears to be overvalued.
The current stock price of $3.18 is trading 39.5% above its estimated GF Value™ of $2.28.
GuruFocus considers Esperion Therapeutics to be Significantly Overvalued.
Key valuation signals for ESPR:
Cash-to-Debt: 0.62 (33% below median its 10-year median of 0.92)
GF Value™: $2.28 vs. price of $3.18 (39.5% above fair value)
Industry Position: 36.7% below the Drug Manufacturers median (#575 of 983)
No single metric tells the full story. See the ESPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
41GF Score
Get the complete analysis for ESPR
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ESPR has been successfully added to your 
